Search

Switzerland: R&D, Manufacturing Merck Invests 275 Million Dollars in New Biotech Development Center

| Editor: Ahlam Rais

Merck’s new biotech development center will be set up in Switzerland and is expected to bridge the gap between research and manufacturing. With this facility, the company aims to make new medicines quickly available to patients.

Related Companies

The construction of the building is expected to be completed in 2021 and the Biotech Development Center is anticipated to be fully operational by the end of 2022.
The construction of the building is expected to be completed in 2021 and the Biotech Development Center is anticipated to be fully operational by the end of 2022.
(Source: Merck)

Corsier-sur-Vevey/Switzerland – Merck has recently announced an investment of 275 million dollars in a new facility in Corsier-sur-Vevey, Switzerland – the Merck Biotech Development Center – dedicated to biotech development and manufacturing for clinical studies. Driven by the growth of the Healthcare business sector R&D pipeline, this investment will help to sustainably secure capacity and high agility to deliver clinical trial material in a cost-effective way, contribute to accelerated development timelines of new biological entities, and address the increasing manufacturing complexity of the next generations of biotech compounds.

“This investment in the Merck Biotech Development Center reflects our commitment to speed up the availability of new medicines for patients in need, and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck, at the groundbreaking ceremony for the new facility held recently.

“Our investment in this biotech development facility in Switzerland is strongly related to the growth and progression of our Healthcare pipeline, and our confidence in its future potential,” said Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare.

Specialist Book „Heat Transfer Technique“The comprehensive standard work „Heat Transfer Technique“ offers not only a detailed and well-founded presentation of the basics of heat transfer technique, but also shows the latest state of the art and the latest regulations in the use of organic fluids. Thematically, the book is rounded off with an overview of property data of organic heat transfer fluids as well as many use cases from practical experience.

Located near Merck’s current biotech commercial manufacturing site in Corsier-sur-Vevey, Switzerland, the Biotech Development Center will bridge together research and manufacturing. The facility will consist of a building providing a total of 15,700 square meters of development space bringing together a cross-functional team of approximately 250 employees spread across different sites today, responsible for advancing Merck’s biotech R&D pipeline by ensuring that Merck’s next generation of biotech therapies are available for clinical trials on time, on quality and on quantity.

Equipped with the most advanced digital solutions and highest technological standards, including continuous manufacturing and laboratory automation, the Biotech Development Center will offer a flexible-by-design infrastructure to readily adapt to emerging needs and technology evolution, as well as open workspaces enabling collaboration, creativity and innovation.

Global Plant Engineering ProjeX-DB is a project database for global plant engineering. Within over 6.400 entries, a variable pricing system and a user friendly interface ProjeX-DB simplifies your working life. Profit from the benefits and register for the demo version.

The Biotech Development Center will showcase Merck’s science and technology across its three business sectors, including Life Sciences’ process solutions for clinical manufacturing and pilot plant operations, as well as Performance Materials’ eyrise dynamic liquid crystal windows as part of the highly efficient energy management of the building. The construction of the building is expected to be completed in 2021 and the Biotech Development Center is anticipated to be fully operational by the end of 2022 following validation by regulatory authorities.

The Biotech Development Center adds to recent investments aiming to further increase Merck’s capacities in the research, development and manufacturing of medicines, such as the expansions of the R&D facility of Billerica, United States, of the biotech manufacturing site of Aubonne, Switzerland, and of the pharma manufacturing site of Darmstadt, Germany.

(ID:46335052)